Shinada, 34 patient favipiravir late treatment study: 7% shorter hospitalization [p=0.84] and 55% faster viral clearance [p=0.04] https://c19p.org/shinada
copied to clipboard
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
et al., Viruses, doi:10.3390/v14040670
Retrospective 17 COVID+ patients treated with favipiravir and 17 matched controls in Japan, showing faster viral clearance with treatment. Favipiravir 3600mg day one, 1600mg per day for up to 14 days.
|
hospitalization time, 7.5% lower, HR 0.93, p = 0.84, treatment 17, control 17.
|
|
viral clearance time, 55.2% lower, HR 0.45, p = 0.04, treatment 17, control 17.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Shinada et al., 3/24/2022, retrospective, Japan, Asia, peer-reviewed, 11 authors, study period 28 May, 2020 - 26 September, 2020, average treatment delay 8.9 days.
Contact:
takashisato1220@gmail.com (corresponding author), kanakoshinada7@gmail.com, mshinopy@gmail.com, shin.ohta0915@gmail.com, miwapicco@outlook.jp, shinkai050169@gmail.com, m-mine@marianna-u.ac.jp, sayamrym@niid.go.jp, yuadachi@niid.go.jp, matt@niid.go.jp, ytakahas@niid.go.jp.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.